DPP4 and Hypoglycemia: Sitagliptin was prescribed for this patient because a growing body of evidence has demonstrated that inhibitors of dipeptidyl peptidase 4 (DPP4) can diminish daily insulin requirements and improve metabolic control without exacerbating the risk of hypoglycemia in T1DM patients (7), (8).